mal vc pab abaep azonafide

Mal-VC-PAB-ABAEP-Azonafide, an ADC (antibody-drug conjugate) linker-drug conjugate, demonstrates potent antitumor activity. It incorporates Azonafide, a cytotoxin, connected through the ADC linker Mal-VC-PAB[1].

SC-VC-PAB-DM1 is a drug-linker conjugate used in Antibody-Drug Conjugates (ADC), combining DM1 (Mertansine, a tubulin inhibitor) with the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, is conjugated via a DBCO-(PEG)3-vc-PAB linker.

Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA is a double-cleavable PEG linker (3-unit and 4-unit) designed for antibody-drug conjugation (ADC).

Mal-PEG4-Val-Cit-PAB-PNP is a cleavable, 4-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-Val-Cit-PAB-OH, a cleavable 4-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which includes metabolites of nemorubicin (MMDX) from liver microsomes and the ADC cytotoxin PNU-159682[1].

Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1].

The chemical compound Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable antibody-drug conjugate (ADC) linker that incorporates a Maleimide group. It is commonly employed in the synthesis of ADCs.

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

Mal-amido-PEG2-Val-Cit-PAB-OH is a bi-functional polyethylene glycol (PEG) linker, composed of two PEG units, that is cleavable and specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, DMEA-PNU-159682, is derived from metabolites of nemorubicin (MMDX) found in liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

MAL-di-EG-Val-Cit-PAB-MMAE consists of the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, both of which are crucial components of antibody-drug conjugates (ADCs).

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a potent tubulin inhibitor and toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2, serving as the cytotoxic component in this formulation.

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-drug conjugate linker, integrating the antitumor antibiotic Duocarmycin SA via the Mal-PEG4-VC-PAB-DMEA-Seco linker, aimed at targeted cancer therapy.

Mal-amido-PEG8-val-gly-PAB-OH, an eight-unit PEG cleavable linker, is frequently employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate utilized in antibody-drug conjugate (ADC) therapy. It comprises the ADC linker Mal-Phe-C4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682, which encompasses metabolites of nemorubicin (MMDX) derived from liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

Mal-PEG4-VC-PAB-DMEA, a cleavable ADC linker incorporating a Maleimide moiety, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8-unit PEG ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable, 2-unit polyethylene glycol (PEG) based ADC linker used in the construction of antibody-drug conjugates (ADCs) [1].

Mal-Phe-C4-Val-Cit-PAB is a cleavable antibody-drug conjugate (ADC) linker with a Maleimide functional group used in ADC synthesis.